3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Odontogenic Cysts
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Radionuclide Imaging
×
90 days
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled